ClinicalTrials.gg
CompletedNCT03362177RECITEUpdated Oct 23, 2026Results posted

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

A Phase 3 interventional study of Romiplostim and Placebo in Chemotherapy-induced Thrombocytopenia, sponsored by Amgen. Completed at 117 sites in 20 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Primary conditionColorectal NeoplasmsRegistry: Gastrointestinal NeoplasmsReclassifiedWhy we changed it
Registry
Gastrointestinal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colorectal Neoplasms
Why
  1. The study's title name Colorectal Neoplasms, a narrower term within Gastrointestinal Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Colorectal Neoplasms by Amgen — 2 open to participants now, 2 under way, 1 of them phase 3. Colorectal Neoplasms · Amgen.

Enrollment
16th of 33
165 · median 160
Started
2019
the only one that year
Phase 3
10 of 40
1 open now
Registered
35th of 40
by date

Among the 40 studies in Colorectal Neoplasms by Amgen, this one is the 16th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2019, is one of 10 in phase 3, and was the 35th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 40 studies in Colorectal Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Colorectal Neoplasms by Amgen, or all of them as a file.
02

Study summary

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

Read the detailed description

RECITE: A phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer

03

Conditions studied

  • Chemotherapy-induced Thrombocytopenia

Browse trials for

Keywords

  • Chemotherapy Induced Thrombocytopenia
  • Gastrointestinal Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
04

In context

Colorectal Neoplasms Reclassified

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's enrollment of 165 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Colorectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study specific activities/procedures or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
  • Males or females greater than or equal to 18 years of age at signing of the informed consent.
  • or cytologically confirmed diagnosis of gastrointestinal, pancreatic, or colorectal adenocarcinoma, defined as cancers of the esophagus (including esophagogastric junction [EGJ] cancer), stomach, pancreas, colon, or rectum. Tumor stage will not affect eligibility.
  • Subjects must be receiving 1 of the following regimens: An oxaliplatin-based chemotherapy regimen, containing 5 FU or capecitabine plus oxaliplatin (irinotecan may be added for FOLFIRINOX or FOLFOXIRI) on a 14- or 21 day schedule, respectively; OR, subjects must have chemotherapy-induced thrombocytopenia from a non-protocol chemotherapy regimen, planning to start treatment with one of the protocol chemotherapy regimens which has been delayed greater than or equal to one week due to chemotherapy-induced thrombocytopenia. Note: Use of these regimens are permitted with (1) anti angiogenic agents (such as bevacizumab) or (2) targeted therapy (such as anti epidermal growth factor receptor agents);
  • Subjects must have a local count ≤ 85 x 10\^9/L on study day 1.
  • Subjects must be at least 14 days removed from the start of the chemotherapy cycle immediately prior to study day 1 if they received FOLFOX, FOLFIRINOX or FOLFOXIRI, and 21 days removed if they received CAPEOX.
  • Subjects must have at least 3 remaining planned cycles of chemotherapy at study enrollment.
  • (ECOG) performance status of 0, 1, or 2.

Exclusion criteria

Exclusion Criteria:

Previous or Current Medical Conditions

  • Acute lymphoblastic leukemia.
  • Acute myeloid leukemia.
  • Any myeloid .
  • Myelodysplastic syndrome. Baseline bone marrow is not required to rule out MDS. However, if a bone marrow biopsy and cytogenetics were performed as part of diagnostic or staging work-up, these results will be collected to confirm.
  • Myeloproliferative disease.
  • Multiple myeloma.
  • Within 4 months prior to enrollment, any history of active congestive heart failure ( [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, (ECG) abnormalities, screening ECG with (QTc) interval of > 470 msec, pericardial disease, or myocardial infarction.
  • Major surgery ≤ 28 days or minor surgery ≤ 3 days prior to enrollment.
  • New or uncontrolled venous thromboembolism or thrombotic events within 3 months prior to screening. To be eligible, subjects must have received at least 14 days of anticoagulation for a new thrombotic event and considered to be both stable and suitable for continued therapeutic anticoagulation during trial participation.
  • History of arterial thrombosis (eg, stroke or ) within 6 months of screening.
  • Evidence of active infection within 2 weeks prior to first dose of study treatment.
  • Known infection. Subjects without a documented diagnosis in their medical history will require a local laboratory assessment at screening. If local laboratory results are not available, use central laboratory results.
  • Known active chronic or C infection. Subjects without a documented diagnosis in their medical history will require a local laboratory assessment at screening. If local laboratory results are not available, use central laboratory results. Hepatitis B and C infection is based on the following results:
  • Positive for hepatitis B surface antigen (HBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B).
  • Negative HBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA suggests occult hepatitis B.
  • Positive virus antibody (HCVAb): hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C.
  • Secondary malignancy within the past 5 years except:
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  • Adequately treated cervical carcinoma in situ without evidence of disease.
  • Adequately treated breast ductal carcinoma in situ without evidence of disease.
  • Prostatic intraepithelial neoplasia without evidence of prostate cancer.
  • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.
  • Malignancy treated with curative intent and with no known active disease present for at least 3 years before enrollment and felt to be at low risk for recurrence by the treating physician
  • Thrombocytopenia due to another etiology other than CIT (eg, chronic liver disease, prior history of immune thrombocytopenia purpura).

Prior/Concomitant Therapy

  • Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor, eltrombopag, recombinant human TPO, any other TPO receptor agonist, or any producing agent.

Prior/Concurrent Clinical Study Experience • Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.

Diagnostic Assessments

  • Anemia ( \<80 g/L [8 g/dL]) on the day of initiation of investigational product as assessed by local labs. Use of red cell transfusions and erythropoietic stimulating agents is permitted throughout the study as per institutional guidelines.
  • Neutropenia ( 1 x 10\^9/L) on the day of initiation of investigational product as assessed by local labs. Use of granulocyte-colony stimulating factor is permitted throughout the study as per institutional guidelines.
  • Abnormal renal function with \< 30 mL/min using the Cockcroft-Gault estimated creatinine clearance as assessed by local laboratory during screening. If local laboratory results are not available, use central laboratory results.
  • Abnormal liver function (total > 3 X ; [ALT] or aspartate aminotransferase [AST] > 3 X ULN for subjects without liver or ≥ 5 X ULN for subjects with liver metastases) as assessed by local laboratory during screening. If local laboratory results are not available, use central laboratory results.

Other Exclusions

  • Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 6 months after treatment (and chemotherapy) discontinuation (females of should only be included after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test.)
  • Females of childbearing potential unwilling to use a highly effective method of during treatment and for an additional 6 months after treatment (and chemotherapy) discontinuation.
  • Males unwilling to use contraception* (male condom or sexual abstinence) or their female partner(s) of childbearing potential who are unwilling to use a highly effective method of contraception during treatment (and chemotherapy) and for an additional 6 months after treatment (and chemotherapy) discontinuation.

    *If the male's sole partner is of non-childbearing potential, he is not required to use additional forms of contraception during the study.

  • Subject has known sensitivity to any of the products to be administered during dosing.
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, COAs) to the best of the subject and investigator's knowledge.
  • History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment (and chemotherapy) and for an additional period of 6 months after treatment (and chemotherapy) discontinuation.
  • Male subjects unwilling to abstain from donating sperm during treatment (and chemotherapy) and for an additional 6 months after treatment (and chemotherapy) discontinuation.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Participants will be enrolled to the study in a 2:1 randomization ratio. Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

    Biological: Romiplostim

  • Placebo comparator
    Placebo

    Participants will be enrolled to the study in a 2:1 randomization ratio. Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

    Other: Placebo

Interventions

  • BiologicalRomiplostim

    This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.

  • OtherPlacebo

    Placebo Comparator

07

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification

    Participants met the criteria of the primary endpoint if there was no thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-trial chemotherapy regimen (cycles were up to 3 weeks). A thrombocytopenia-induced modification was defined as any dose reduction, dose delay, dose omission, and/or early chemotherapy treatment discontinuation due to low platelet counts less than 100 x 10\^9/L. The 95% confidence interval (CI) is based on the exact Clopper-Pearson method.

    Time frame: Day 1 up to Week 12

Secondary outcomes

  1. Platelet Count Nadir at the End of the Treatment Period

    The platelet count nadir from the first on-trial chemotherapy through the end of the treatment period is presented. The least squares (LS) mean platelet count nadirs were estimated using a general linear model which included treatment, stratification factors, and the interaction between treatment and the stratification factors (tumor type and baseline platelet count).

    Time frame: Up to 21 weeks

  2. Kaplan-Meier Estimate of Time to First Platelet Response

    Platelet response was defined as achieving a platelet count of ≥ 100 x 10\^9/L in the absence of platelet transfusions during the preceding 7 days. Participants who did not achieve a response event during the treatment period were censored at their last platelet count assessment up to end of treatment period or at the randomization date if they did not have any post-baseline platelet assessments.

    Time frame: Up to 21 weeks

  3. Duration-adjusted Event Rate of Bleeding Events in the Treatment Period

    The duration-adjusted adverse event (AE) incidence rate was the number of events per 100 subject-years from the trial day 1 until the date of last dose of investigational product + 30 days, or end of trial, whichever is earlier. It was calculated as: duration-adjusted event rate per 100 subject years (n/Subj-yr) x 100. The duration-adjusted event rate was assessed for Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 bleeding events. CTCAE grading for AEs ranges from Grade 1 (mild) to Grade 5 (death related to AE). Grade 2 AEs were moderate.

    Time frame: Up to 21 weeks

  4. Overall Survival

    Overall survival was defined as the time calculated from trial Day 1 to death. Participants who did not died were censored.

    Time frame: From Day 1 up to 1 year after last dose of investigational product (IP) (max 1869 days)

  5. Percentage of Participants Who Had Platelet Transfusions During the Treatment Period

    Participants who had at least 1 platelet transfusion during the treatment period.

    Time frame: Up to 21 weeks

  6. Percentage of Participants Who Achieved a Platelet Count ≥ 100 x 10^9/L

    The number of participants who achieved a platelet count ≥ 100 x 10\^9/L at any time after trial Day 1 to Week 4 (7 days after the planned third dose of IP). If a platelet transfusion occurred during the 7 days preceding a platelet count, then that platelet count was not considered as achieving the endpoint even if it is ≥ 100 x 109/L. Participants who had no platelet counts during this period were considered as not achieving achieved a platelet count ≥ 100 x 109/L. For participants who never received IP, the participants are considered as not achieving a platelet count ≥ 100 x 109/L. Weeks with no platelet count measurements (missing data) were considered as not achieving a platelet count ≥ 100 x 109/L.

    Time frame: Day 1 to Week 4

  7. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Fatal AEs

    An AE was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was an AE that started on or after the first dose of IP up to 30 days after the end of investigational product or last dose of on-trial chemotherapy (up to 3 cycles), whichever occurs later. Clinically significant changes in laboratory values were considered AEs. A SAE was defined as any untoward medical occurrence that, met at least 1 ofthe following criteria: resulted in death (fatal), immediately life-threatening,required in-patient hospitalization or prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity or was a congenitalanomaly/birth defect.

    Time frame: From first dose of IP to 30 days after last dose of IP: median (min, max) duration was 86.0 (31.0, 184.0) days

  8. Number of Participants Who Developed Anti-romiplostim Antibodies and Anti-thrombopoietin (TPO) Antibodies

    Blood samples were collected from all participants for the measurement of anti-romiplostim and anti-TPO binding antibodies. Participants were tested for the presence of anti-romiplostim and anti-TPO antibodies at baseline (pre-existing antibody) and post-baseline (developed antibody). Samples testing positive for binding antibodies were also be tested for neutralizing antibodies.

    Time frame: Up to 21 weeks

  9. Number of Participants Who Reported Myelodysplastic Syndromes (MDS) and SecondaryMalignancies

    Events were identified using narrow search of pre-defined list of preferred terms for myelodysplastic syndromes (SMQ). Secondary malignancies included progression from myelodysplastic syndrome to acute myeloid leukemia (AML).

    Time frame: From Day 1 up to 1 year after last dose of IP (max 1869 days)

08

Results

Posted Feb 11, 2026

Participant flow

Participants were enrolled in 55 trial centers in Bulgaria, Greece, Italy, Poland, Portugal, Romania, Spain, Argentina, Brazil, Canada, Mexico, Russia, Turkey, and the United States.

Participant flow — Overall Study
MilestoneRomiplostimPlacebo
Started10956
Safety analysis set11055
Completed3426
Not completed7530
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject128
Withdrew: Decision by sponsor60
Withdrew: Death5522

Outcome measures

PrimaryPercentage of Participants Who Had Thrombocytopenia-induced Dose Modification

Participants met the criteria of the primary endpoint if there was no thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-trial chemotherapy regimen (cycles were up to 3 weeks). A thrombocytopenia-induced modification was defined as any dose reduction, dose delay, dose omission, and/or early chemotherapy treatment discontinuation due to low platelet counts less than 100 x 10\^9/L. The 95% confidence interval (CI) is based on the exact Clopper-Pearson method.

Time frame:
Day 1 up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification
percentage of participantsRomiplostimPlacebo
Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification84.4 (76.21 to 90.64)35.7 (23.36 to 49.64)
Statistical analysis
  • Romiplostim vs Placebo · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was from the stratified exact test of null hypothesis: common treatment odds ratio=1.) · Odds ratio (or): 10.16 · 95% CI 4.44 to 23.72Odds ratio (romiplostim/placebo) was calculated by using two-sided Cochran-Mantel-Haenszel (CMH) tests considering stratification factors (tumor type and baseline platelet count).
SecondaryPlatelet Count Nadir at the End of the Treatment Period

The platelet count nadir from the first on-trial chemotherapy through the end of the treatment period is presented. The least squares (LS) mean platelet count nadirs were estimated using a general linear model which included treatment, stratification factors, and the interaction between treatment and the stratification factors (tumor type and baseline platelet count).

Time frame:
Up to 21 weeks
Reported as:
Least squares mean · 10^9 platelets per L
Platelet Count Nadir at the End of the Treatment Period
10^9 platelets per LRomiplostimPlacebo
Platelet Count Nadir at the End of the Treatment Period77.3 (66.5 to 88.0)51.1 (36.4 to 65.8)
Statistical analysis
  • Romiplostim vs Placebo · General linear model · p = 0.005 · Mean difference: 26.1 · 95% CI 7.9 to 44.4Romiplostim - placebo
SecondaryKaplan-Meier Estimate of Time to First Platelet Response

Platelet response was defined as achieving a platelet count of ≥ 100 x 10\^9/L in the absence of platelet transfusions during the preceding 7 days. Participants who did not achieve a response event during the treatment period were censored at their last platelet count assessment up to end of treatment period or at the randomization date if they did not have any post-baseline platelet assessments.

Time frame:
Up to 21 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimate of Time to First Platelet Response
weeksRomiplostimPlacebo
Kaplan-Meier Estimate of Time to First Platelet Response1.1 (NA to NA)2.1 (1.1 to 3.0)
Statistical analysis
  • Romiplostim vs Placebo · Cox proportional hazards · p = < 0.001 · Hazard ratio (hr): 2.673 · 95% CI 1.808 to 3.952Hazard ratio is romiplostim vs. placebo. A value \> 1.0 indicates a higher average event rate and shorter time to response for romiplostim relative to placebo.
SecondaryDuration-adjusted Event Rate of Bleeding Events in the Treatment Period

The duration-adjusted adverse event (AE) incidence rate was the number of events per 100 subject-years from the trial day 1 until the date of last dose of investigational product + 30 days, or end of trial, whichever is earlier. It was calculated as: duration-adjusted event rate per 100 subject years (n/Subj-yr) x 100. The duration-adjusted event rate was assessed for Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 bleeding events. CTCAE grading for AEs ranges from Grade 1 (mild) to Grade 5 (death related to AE). Grade 2 AEs were moderate.

Time frame:
Up to 21 weeks
Reported as:
Number · bleeding events per 100 subject-years
Duration-adjusted Event Rate of Bleeding Events in the Treatment Period
bleeding events per 100 subject-yearsRomiplostimPlacebo
Duration-adjusted Event Rate of Bleeding Events in the Treatment Period4.07.6
Statistical analysis
  • Romiplostim vs Placebo · Andersen-Gill model · p = 0.63 · Hazard ratio (hr): 0.53 · 95% CI 0.04 to 6.77Romiplostim/Placebo
SecondaryOverall Survival

Overall survival was defined as the time calculated from trial Day 1 to death. Participants who did not died were censored.

Time frame:
From Day 1 up to 1 year after last dose of investigational product (IP) (max 1869 days)
Reported as:
Median · months
Overall Survival
monthsRomiplostimPlacebo
Overall Survival21.0 (15.4 to 45.3)46.0 (22.2 to NA)
SecondaryPercentage of Participants Who Had Platelet Transfusions During the Treatment Period

Participants who had at least 1 platelet transfusion during the treatment period.

Time frame:
Up to 21 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Had Platelet Transfusions During the Treatment Period
percentage of participantsRomiplostimPlacebo
Percentage of Participants Who Had Platelet Transfusions During the Treatment Period1.8 (0.22 to 6.47)0.0 (0.00 to 6.38)
SecondaryPercentage of Participants Who Achieved a Platelet Count ≥ 100 x 10^9/L

The number of participants who achieved a platelet count ≥ 100 x 10\^9/L at any time after trial Day 1 to Week 4 (7 days after the planned third dose of IP). If a platelet transfusion occurred during the 7 days preceding a platelet count, then that platelet count was not considered as achieving the endpoint even if it is ≥ 100 x 109/L. Participants who had no platelet counts during this period were considered as not achieving achieved a platelet count ≥ 100 x 109/L. For participants who never received IP, the participants are considered as not achieving a platelet count ≥ 100 x 109/L. Weeks with no platelet count measurements (missing data) were considered as not achieving a platelet count ≥ 100 x 109/L.

Time frame:
Day 1 to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Platelet Count ≥ 100 x 10^9/L
percentage of participantsRomiplostimPlacebo
Percentage of Participants Who Achieved a Platelet Count ≥ 100 x 10^9/L96.3 (90.87 to 98.99)66.1 (52.19 to 78.19)
Statistical analysis
  • Romiplostim vs Placebo · Odds ratio (or): 16.19 · 95% CI 4.38 to 88.85
SecondaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Fatal AEs

An AE was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was an AE that started on or after the first dose of IP up to 30 days after the end of investigational product or last dose of on-trial chemotherapy (up to 3 cycles), whichever occurs later. Clinically significant changes in laboratory values were considered AEs. A SAE was defined as any untoward medical occurrence that, met at least 1 ofthe following criteria: resulted in death (fatal), immediately life-threatening,required in-patient hospitalization or prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity or was a congenitalanomaly/birth defect.

Time frame:
From first dose of IP to 30 days after last dose of IP: median (min, max) duration was 86.0 (31.0, 184.0) days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Fatal AEs
ParticipantsRomiplostimPlacebo
TEAEs9634
SAEs233
Fatal AEs20
SecondaryNumber of Participants Who Developed Anti-romiplostim Antibodies and Anti-thrombopoietin (TPO) Antibodies

Blood samples were collected from all participants for the measurement of anti-romiplostim and anti-TPO binding antibodies. Participants were tested for the presence of anti-romiplostim and anti-TPO antibodies at baseline (pre-existing antibody) and post-baseline (developed antibody). Samples testing positive for binding antibodies were also be tested for neutralizing antibodies.

Time frame:
Up to 21 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-romiplostim Antibodies and Anti-thrombopoietin (TPO) Antibodies
ParticipantsRomiplostimPlacebo
Romiplostim: Binding antibodypositive at or before baseline20
Romiplostim: Neutralizingantibody positive at or beforebaseline00
Romiplostim: Binding antibodypositive post-baseline with anegative or no result at baseline10
Romiplostim: Neutralizingantibody positive post-baselinewith a negative or no result atbaseline00
TPO: Binding antibody positiveat or before baseline00
TPO: Neutralizing antibodypositive at or before baseline00
TPO: Binding antibody positivepost-baseline with a negative orno result at baseline10
TPO: Neutralizing antibodypositive post-baseline with anegative or no result at baseline00
SecondaryNumber of Participants Who Reported Myelodysplastic Syndromes (MDS) and SecondaryMalignancies

Events were identified using narrow search of pre-defined list of preferred terms for myelodysplastic syndromes (SMQ). Secondary malignancies included progression from myelodysplastic syndrome to acute myeloid leukemia (AML).

Time frame:
From Day 1 up to 1 year after last dose of IP (max 1869 days)
Reported as:
Count of participants · Participants
Number of Participants Who Reported Myelodysplastic Syndromes (MDS) and SecondaryMalignancies
ParticipantsRomiplostimPlacebo
MDS10
Secondary Malignancy23

Adverse events

Collected over For Mortality - From Enrollment to End of trial: median (min, max) time on trial was 529.0 (8.0, 1869.0) days. For TEAEs - From first dose of IP to 30 days after last dose of IP: median (min, max) duration was 86.0 (31.0, 184.0) days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo25/55 (45.5%)3/55 (5.5%)28/55 (50.9%)
Romiplostim58/110 (52.7%)23/110 (20.9%)76/110 (69.1%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlaceboRomiplostim
AnaemiaBlood and lymphatic system disorders0/553/110
COVID-19 pneumoniaInfections and infestations0/553/110
Intestinal obstructionGastrointestinal disorders1/550/110
Rectal haemorrhageGastrointestinal disorders1/551/110
PyrexiaGeneral disorders0/552/110
Anaphylactic reactionImmune system disorders1/550/110
PeritonitisInfections and infestations0/552/110
Febrile neutropeniaBlood and lymphatic system disorders0/551/110
LeukopeniaBlood and lymphatic system disorders0/551/110
ThrombocytopeniaBlood and lymphatic system disorders0/551/110
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboRomiplostim
ThrombocytopeniaBlood and lymphatic system disorders11/5521/110
NeutropeniaBlood and lymphatic system disorders8/5521/110
NauseaGastrointestinal disorders7/5514/110
AnaemiaBlood and lymphatic system disorders5/5513/110
DiarrhoeaGastrointestinal disorders4/5513/110
Neuropathy peripheralNervous system disorders5/5512/110
HypertensionVascular disorders0/5512/110
VomitingGastrointestinal disorders4/5511/110
FatigueGeneral disorders3/5511/110
LeukopeniaBlood and lymphatic system disorders1/5510/110

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)RomiplostimPlaceboTotal
<=18 years000
Between 18 and 65 years573390
>=65 years522375
Age, Continuous
Age, Continuous(years)RomiplostimPlaceboTotal
Mean61.6 ± 10.960.9 ± 11.561.4 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)RomiplostimPlaceboTotal
Female462066
Male633699
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RomiplostimPlaceboTotal
Hispanic or Latino281139
Not Hispanic or Latino8145126
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RomiplostimPlaceboTotal
Black (or African American)426
White9454148
Other11011
Mean Baseline Platelet Count
Mean Baseline Platelet Count(10^9 platelets per L)RomiplostimPlaceboTotal
Mean67.073 ± 13.66863.989 ± 14.70966.027 ± 14.062
09

Study locations

117 sites
  • Saint Bernards Medical Center
    Jonesboro, Arkansas 72401, United States
  • Pacific Cancer Medical Center Inc
    Anaheim, California 92801, United States
  • University of California Irvine
    Orange, California 92868, United States
  • Colorado West Healthcare System dba Grand Valley Oncology
    Grand Junction, Colorado 81505, United States
  • Mid Florida Hematology and Oncology Centers PA
    Orange City, Florida 32763, United States
  • Oncology and Hematology Associates of West Broward, PA
    Tamarac, Florida 33321, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Orchard Healthcare Research Inc
    Skokie, Illinois 60076, United States
  • Christus Saint Frances Cabrini Hospital
    Alexandria, Louisiana 71301, United States
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Christus Highland Cancer Treatment Center
    Shreveport, Louisiana 71105, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • American Oncology Partners, PA
    Bethesda, Maryland 20817, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Hattiesburg Clinic Hematology/Oncology
    Hattiesburg, Mississippi 39401, United States
  • Oncology Hematology Associates
    Springfield, Missouri 65807, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Regional Cancer Care Associates
    Sparta, New Jersey 78071, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Medical Oncology Associates PS
    Spokane, Washington 99208, United States
  • Yakima Valley Memorial Hospital
    Yakima, Washington 98902, United States
  • Hospital Universitario Fundacion Favaloro
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1093AAS, Argentina
  • Instituto Oncologico Cordoba
    Córdoba, Córdoba Province 5003, Argentina
  • Centro de Investigaciones Clínicas Clínica Viedma
    Viedma, Río Negro Province 8500, Argentina
  • Centro de Diagnostico Investigacion y Tratamiento
    Salta, 4400, Argentina
  • Landeskrankenhaus Steyr
    Steyr, 4400, Austria
  • Universitaetsklinikum Allgemeines Krankenhaus Wien
    Vienna, 1090, Austria
  • Instituto de Oncologia do Parana
    Curitiba, Paraná 80530-010, Brazil
  • Vencer e Oncoclinica
    Teresina, Piauí 64049-200, Brazil
  • Centro de Pesquisa da Serra Gaucha - Cepesg
    Caxias do Sul, Rio Grande do Sul 95020-450, Brazil
  • Catarina Pesquisa Clinica
    Itajaí, Santa Catarina 88301-220, Brazil
  • Loema Instituto de Pesquisa Clinica e Consultores Ltda
    Campinas, São Paulo 13010-001, Brazil
  • Casa de Saude Santa Marcelina
    São Paulo, São Paulo 08270-120, Brazil
  • Complex Oncology Center - Ruse EOOD
    Rousse, 7002, Bulgaria
  • Medical Center Nadezhda Clinical EOOD
    Sofia, 1330, Bulgaria
  • Specialized Hospital for Active Treatment of Oncology EAD
    Sofia, 1756, Bulgaria
  • Cape Breton Cancer Centre, Nova Scotia Health Authority
    Sydney, Nova Scotia B1P 1P3, Canada
  • Grand River Regional Cancer Centre at Grand River Hospital
    Kitchener, Ontario N2G 1G3, Canada
  • Fundacion Colombiana de Cancerologia Clinica Vida
    Medellín, Antioquia 050030, Colombia
  • Oncomedica Imat
    Montería, Departamento de Córdoba 230002, Colombia
  • Centro Medico Imbanaco
    Cali, Valle del Cauca Department 760042, Colombia
  • Centre Hospitalier Universitaire de Brest
    Brest, 29609, France
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • Hopital Foch
    Suresnes, 92150, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • General Hospital of Athens Laiko
    Athens, 11526, Greece
  • Aretaieio Hospital
    Athens, 11528, Greece
  • Evgenidio Hospital I Agia Trias
    Athens, 11528, Greece
  • Attikon University Hospital
    Athens, 12462, Greece
  • General Oncology Hospital of Kifissia Agioi Anargyroi
    Athens, 14564, Greece
  • University Hospital of Patras
    Pátrai, 26504, Greece
  • Agios Loukas Clinic
    Thessaloniki, 55236, Greece
  • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
    Budapest, 1097, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktatokorhaz
    Győr, 9024, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar
    Szeged, 6720, Hungary
  • Azienda Socio Sanitaria Territoriale di Cremona
    Cremona, 26100, Italy
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino Ospedale Molinette
    Torino, 10126, Italy
  • Oncotech
    La Paz, Baja California Sur 23040, Mexico
  • Centro de Atencion e Investigacion Cardiovascular del Potosi Sc
    San Luis Potosí City, San Luis Potosí 78200, Mexico
  • Centro Medico Nacional Siglo XXI
    México, 06720, Mexico
  • Oaxaca Site Management Organization SC
    Oaxaca City, 68000, Mexico
  • Hospital Goyeneche
    Arequipa, 04001, Peru
  • Oncosalud
    Lima, 15036, Peru
  • Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
    Biała Podlaska, 21-500, Poland
  • Powiatowe Centrum Zdrowia w Brzezinach Sp Z o o
    Brzeziny, 95-060, Poland
  • Uniwersytecki Szpital Kliniczny w Poznaniu
    Poznan, 60-569, Poland
  • Uniwersytecki Szpital Kliniczny w Poznaniu
    Poznan, 60-780, Poland
  • Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
  • Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano
    Matosinhos Municipality, 4464-513, Portugal
  • Centro Hospitalar Universitario do Porto, EPE - Hospital de Santo Antonio
    Porto, 4099-001, Portugal
  • Centro Hospitalar Universitario de Sao Joao, EPE - Hospital Sao Joao
    Porto, 4200-319, Portugal
  • Centro Hospitalar Tras-os-Montes e Alto Douro EPE - Unidade de Vila Real
    Vila Real, 5000-508, Portugal
  • Policlinica de Diagnostic Rapid
    Brasov, 500152, Romania
  • Fundeni Clinical Institute for Digestive Disorders and Liver Transplantation
    Bucharest, 022328, Romania
  • Spitalul Clinic al Cailor Ferate Cluj Napoca
    Cluj-Napoca, 400015, Romania
  • SC Medisprof SRL
    Cluj-Napoca, 400124, Romania
  • Centrul de Oncologie Sf Nectarie SRL
    Craiova, 200347, Romania
  • Institutul Regional de Oncologie Iasi
    Iași, 700483, Romania
  • SC Oncomed SRL
    Timișoara, 300239, Romania
  • SBHI of Arkhangelsk region Arkhangelsk clinical oncology dispensary
    Arkhangelsk, 163045, Russia
  • Autonomic SHI Republican clinical oncology dispensary of MoH of the Republic of Tatarstan
    Kazan', 420029, Russia
  • Clinical hospital 2, Group of companies medsi
    Moscow, 125284, Russia
  • Medsi Group
    Moscow Region, 143442, Russia
  • LLC Tonus
    Nizhny Novgorod, 603089, Russia
  • Omsk Regional Clinical Oncology Dispensary
    Omsk, 644013, Russia
  • State budget institution of public health Pyatigorsk oncology dispensary
    Pyatigorsk, 357502, Russia
  • State Institution of Public Health
    Ryazan, 390011, Russia
  • Leningrad Regional Oncology Dispensary na L D Roman
    Saint Petersburg, 191104, Russia
  • FSBI Scientific and Research Oncology Institute named after N N Petrov
    Saint Petersburg, 197758, Russia
  • State Institution of Public Health Oncology Dispensary 2 of Public Health Krasnodar Region
    Sochi, 354057, Russia
  • State Institution of Public Health Tambov Regional Oncology Dispensary
    Tambov, 390013, Russia
  • Respublican clinical oncology dispensary Minzdrava of Republic of Bashkortostan
    Ufa, 450054, Russia
  • Hospital Clinico Universitario San Cecilio
    Granada, Andalusia 18016, Spain
  • Hospital Clinico Universitario de Salamanca
    Salamanca, Castille and León 37007, Spain
  • Hospital Universitario Arnau de Vilanova Lleida
    Lleida, Catalonia 25198, Spain
  • Hospital Universitari Sant Joan de Reus
    Reus, Catalonia 43204, Spain
  • Complexo Hospitalario Universitario de Ourense
    Ourense, Galicia 32005, Spain

Showing the first 100 of 117 sites across 20 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Al-Samkari H, Munoz C, Geredeli C, Korantzis I, Gonzalez Astorga B, Arslan C, Cordeiro Camargo JF, Scotte F, Borges G, Wang K, Eisen M, Kuter DJ, Soff GA. Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. N Engl J Med. 2026 Mar 12;394(11):1061-1073. doi: 10.1056/NEJMoa2511882. PubMed 41812193 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jan 2024, 51 months.

Results were first posted in Feb 2026, 2 years after primary completion. A results delay was requested in Jan 2025.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 51 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2017
First posted
Dec 5, 2017
StartActual
Sep 30, 2019
Primary completionActual
Jan 25, 2024
CompletionActual
Jan 9, 2025
Results delay requested
Jan 17, 2025
Results first posted
Feb 11, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, site details and references
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT03362177
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 5, 2017
Start date
Sep 30, 2019
Primary completion
Jan 25, 2024
Completion
Jan 9, 2025
Results posted
Feb 11, 2026
Last update
Oct 23, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion